Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 308, Issue 5, 2015, Pages R431-R438

  Blevins, James E ^a,b   Graham, James L ^c   Morton, Gregory J ^b   Bales, Karen L ^c   Schwartz, Michael W ^b   Baskin, Denis G ^a,b   Havel, Peter J ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Energy expenditure; Food intake; Obesity; Oxytocin

Indexed keywords

ADIPONECTIN; FATTY ACID; FRUCTOSE; GLUCOSE; GLYCEROL; INSULIN; LEPTIN; OXYTOCIN; TRIACYLGLYCEROL; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BIOLOGICAL MARKER; CARBOHYDRATE DIET; LIPID;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CALORIMETRY; CHOLESTEROL BLOOD LEVEL; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHESUS MONKEY; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BLOOD; CARBOHYDRATE DIET; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; EATING; ENERGY METABOLISM; FEEDING BEHAVIOR; LIPOLYSIS; PATHOPHYSIOLOGY; PSYCHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BIOMARKERS; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EATING; ENERGY METABOLISM; FEEDING BEHAVIOR; FRUCTOSE; INJECTIONS, SUBCUTANEOUS; LIPIDS; LIPOLYSIS; MACACA MULATTA; MALE; OBESITY; OXYTOCIN; TIME FACTORS; WEIGHT LOSS;

EID: 84923869684     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00441.2014     Document Type: Article

References (73)

1. Altirriba J, Poher AL, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, Dulloo A, Rohner-Jeanrenaud F. divergent effects of oxy-tocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology: en20141466, 2014.
2. Amico JA, Vollmer RR, Cai HM, Miedlar JA, Rinaman L. Enhanced initial and sustained intake of sucrose solution in mice with an oxytocin gene deletion. Am J Physiol Regul Integr Comp Physiol 289: R1798–R1806, 2005.
3. Arletti R, Benelli A, Bertolini A. Influence of oxytocin on feeding behavior in the rat. Peptides 10: 89–93, 1989.
4. Arletti R, Benelli A, Bertolini A. Oxytocin inhibits food and fluid intake in rats. Physiol Behav 48: 825–830, 1990.
5. Armour JA, Klassen GA. Oxytocin modulation of intrathoracic sympathetic ganglionic neurons regulating the canine heart. Peptides 11: 533–537, 1990.
6. Backman SB, Henry JL. Effects of oxytocin and vasopressin on thoracic sympathetic preganglionic neurones in the cat. Brain Res Bull 13: 679–684, 1984.
7. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Trans Med 3: 108–112, 2011.
8. Blevins JE, Schwartz MW, Baskin DG. Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. Am J Physiol Regul Integr Comp Physiol 287: R87–R96, 2004.
9. Boccia ML, Goursaud AP, Bachevalier J, Anderson KD, Pedersen CA. Peripherally administered non-peptide oxytocin antagonist, L368,899, accumulates in limbic brain areas: a new pharmacological tool for the study of social motivation in non-human primates. Horm Behav 52: 344–351, 2007.
10. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79: 537–543, 2004.
11. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Ampah SB, Saville BR, Havel PJ. Fish oil supplementation ameliorates fructoseinduced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr 144: 5–11, 2014.
12. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Wang W, Saville BR, Havel PJ. Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Trans Sci 4: 243–252, 2011.
13. Butler AA, Kozak LP. A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59: 323–329, 2010.
14. Calcagnoli F, Meyer N, de Boer SF, Althaus M, Koolhaas JM. Chronic enhancement of brain oxytocin levels causes enduring anti-aggressive and pro-social explorative behavioral effects in male rats. Horm Behav 65: 427–433, 2014.
15. Camerino C. Low sympathetic tone and obese phenotype in oxytocindeficient mice. Obesity 17: 980–984, 2009.
16. Carson DS, Hunt GE, Guastella AJ, Barber L, Cornish JL, Arnold JC, Boucher AA, McGregor IS. Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biol 15: 448–463, 2010.
17. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 14: 383–392, 2013.
18. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocrine Rev 29: 777–822, 2008.
19. Covasa M, Grahn J, Ritter RC. High fat maintenance diet attenuates hindbrain neuronal response to CCK. Regul Pept 86: 83–88, 2000.
20. Covasa M, Ritter RC. Rats maintained on high-fat diets exhibit reduced satiety in response to CCK and bombesin. Peptides 19: 1407–1415, 1998.
21. Covasa M, Ritter RC. Reduced sensitivity to the satiation effect of intestinal oleate in rats adapted to high-fat diet. Am J Physiol Regul Integr Comp Physiol 277: R279–R285, 1999.
22. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, Piscitelli F, Legros JJ, Geenen V, Foti M, Wahli W, Di Marzo V, Rohner-Jeanrenaud F. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLos One 6: e25565, 2011.
23. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415–1428, 2005.
24. Freeman SM, Inoue K, Smith AL, Goodman MM, Young LJ. The neuroanatomical distribution of oxytocin receptor binding and mRNA in the male rhesus macaque (Macaca mulatta). Psychoneuroendocrinology 45: 128–141, 2014.
25. Gajdosechova L, Krskova K, Segarra AB, Spolcova A, Suski M, Olszanecki R, Zorad S. Hypooxytocinaemia in obese Zucker rats relates to oxytocin degradation in liver and adipose tissue. J Endocrinol 220: 333–343, 2014.
26. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81: 629–683, 2001.
27. Gould BR, Zingg HH. Mapping oxytocin receptor gene expression in the mouse brain and mammary gland using an oxytocin receptor-LacZ reporter mouse. Neuroscience 122: 155–167, 2003.
28. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28: 629–636, 2008.
29. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutrition Rev 63: 133–157, 2005.
30. Herisson FM, Brooks LL, Waas JR, Levine AS, Olszewski PK. Functional relationship between oxytocin and appetite for carbohydrates versus saccharin. Neuroreport 25: 909–914, 2014.
31. Hicks C, Jorgensen W, Brown C, Fardell J, Koehbach J, Gruber CW, Kassiou M, Hunt GE, McGregor IS. The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats. J Neuroendocrinol 24: 1012–1029, 2012.
32. Higa KT, Mori E, Viana FF, Morris M, Michelini LC. Baroreflex control of heart rate by oxytocin in the solitary-vagal complex. Am J Physiol Regul Integr Comp Physiol 282: R537–R545, 2002.
33. Holder JL Jr, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet 9: 101–108, 2000.
34. Jansen AS, Wessendorf MW, Loewy AD. Transneuronal labeling of CNS neuropeptide and monoamine neurons after pseudorabies virus injections into the stellate ganglion. Brain Res 683: 1–24, 1995.
35. Kasahara Y, Sato K, Takayanagi Y, Mizukami H, Ozawa K, Hidema S, So KH, Kawada T, Inoue N, Ikeda I, Roh SG, Itoi K, Nishimori K. Oxytocin receptor in the hypothalamus is sufficient to rescue normal thermoregulatory function in male oxytocin receptor knockout mice. Endocrinology 154: 4305–4315, 2013.
36. Kendrick KM. Oxytocin, motherhood and bonding. Exp Physiol 85 Spec No: 111S–124S, 2000.
37. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774–781, 2007.
38. Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, Pranger L, Cowley MA, Grove KL, Culler MD. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62: 490–497, 2013.
39. Kublaoui BM, Gemelli T, Tolson KP, Wang Y, Zinn AR. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol Endocrinol 22: 1723–1734, 2008.
40. Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Milano) 3: 1169–1177, 2011.
41. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh IS, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptinindependent melanocortin pathway. Cell Metab 10: 355–365, 2009.
42. Malik VS, Popkin BM, Bray GA, Despres JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 121: 1356–1364, 2010.
43. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr 84: 274–288, 2006.
44. Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden- Hanson T, Baskin DG, Schwartz MW, Blevins JE. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302: E134–E144, 2012.
45. Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden- Hanson T, Baskin DG, Schwartz MW, Blevins JE. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302: E134–E144, 2012.
46. Muchmore DB, Little SA, de Haen C. A dual mechanism of action of ocytocin in rat epididymal fat cells. J Biol Chem 256: 365–372, 1981.
47. Mullis K, Kay K, Williams DL. Oxytocin action in the ventral tegmental area affects sucrose intake. Brain Res 1513: 85–91, 2013.
48. Noble EE, Billington CJ, Kotz CM, Wang C. Oxytocin in the ventromedial hypothalamic nucleus reduces feeding and acutely increases energy expenditure. Am J Physiol Regul Integr Comp Physiol 307: R737–R748, 2014.
49. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. In: National Center for Health Statistics Data Brief, US Departmentof Heath and Human Services, Hyattsville, MD, 2012.
50. Oldfield BJ, Giles ME, Watson A, Anderson C, Colvill LM, McKinley MJ. The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat. Neuroscience 110: 515–526, 2002.
51. Olson BR, Drutarosky MD, Stricker EM, Verbalis JG. Brain oxytocin receptor antagonism blunts the effects of anorexigenic treatments in rats: evidence for central oxytocin inhibition of food intake. Endocrinology 129: 785–791, 1991.
52. Olszewski PK, Klockars A, Olszewska AM, Fredriksson R, Schioth HB, Levine AS. Molecular, immunohistochemical, and pharmacological evidence of oxytocin’s role as inhibitor of carbohydrate but not fat intake. Endocrinology 151: 4736–4744, 2010.
53. Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, Hallschmid M. Oxytocin reduces reward-driven food intake in humans. Diabetes 62: 3418–3425, 2013.
54. Page KA, Chan O, Arora J, Belfort-Deaguiar R, Dzuira J, Roehmholdt B, Cline GW, Naik S, Sinha R, Constable RT, Sherwin RS. Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. JAMA 309: 63–70, 2013.
55. Sawchenko PE, Swanson LW. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol 205: 260–272, 1982.
56. Schaffler A, Binart N, Scholmerich J, Buchler C. Hypothesis paper Brain talks with fat– evidence for a hypothalamic-pituitary-adipose axis? Neuropeptides 39: 363–367, 2005.
57. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nature Med 12: 75–80, 2006.
58. Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipid 19: 16–24, 2008.
59. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119: 1322–1334, 2009.
60. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 80: 573–579, 1995.
61. Swarbrick MM, Evans DS, Valle MI, Favre H, Wu SH, Njajou OT, Li R, Zmuda JM, Miljkovic I, Harris TB, Kwok PY, Vaisse C, Hsueh WC. Replication and extension of association between common genetic variants in SIM1 and human adiposity. Obesity (Silver Spring) 19: 2394–2403, 2011.
62. Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport 19: 951–955, 2008.
63. Tsuda T, Ueno Y, Yoshikawa T, Kojo H, Osawa T. Microarray profiling of gene expression in human adipocytes in response to anthocyanins. Biochem Pharmacol 71: 1184–1197, 2006.
64. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, Zhou L, Wada R, Hecht R, Xu J. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153: 4192–4203, 2012.
65. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109: 1–9, 1949.
66. Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E, Blackburn H, Loos RJ, Wareham NJ, O’Rahilly S, Hurles ME, Barroso I, Farooqi IS. Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nature Genet 45: 513–517, 2013.
67. Wu Z, Xu Y, Zhu Y, Sutton AK, Zhao R, Lowell BB, Olson DP, Tong Q. An obligate role of oxytocin neurons in diet induced energy expenditure. PLos One 7: e45167, 2012.
68. Yamashita M, Takayanagi Y, Yoshida M, Nishimori K, Kusama M, Onaka T. Involvement of prolactin releasing peptide in activation of oxytocin neurones in response to food intake. J Neuroendocrinol 25: 455–465, 2013.
69. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311: 74–86, 2014.
70. Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, Nishimori K. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 29: 2259–2271, 2009.
71. Zhang G, Bai H, Zhang H, Dean C, Wu Q, Li J, Guariglia S, Meng Q, Cai D. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 69: 523–535, 2011.
72. Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab 301: E1004–E1012, 2011.
73. Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, Cai D. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLos One 8: e61477, 2013.